CMED Just Beat Earnings by 11 Cents and Nobody Is Talking About It

Everyone's inbox this week was stuffed with Iran conflict updates, Palantir's 15% weekly rip, and Trump promising to quadruple production of something called 'Exquisite Class' weaponry — which sounds like a cologne line but is apparently very serious defense hardware. Fair enough. But buried under the geopolitical noise was Carlsmed (CMED), which reported a loss of 32 cents vs. the estimated 43-cent loss, beat revenue at $15.2M vs. the $14.5M estimate, and watched its shares jump 16% in response. A beat is a beat.

What does Carlsmed actually do? AI-enabled personalized spine surgery — 3D patient models, custom 3D-printed implants, and clinical data showing a 74% reduction in reoperation rates at the two-year mark. That's not a pitch deck number, that's the kind of outcome that makes hospital procurement officers actually pick up the phone. The Bloomberg Businessweek interview this week laid it out cleanly, and the market responded accordingly.

Meanwhile, Bloomberg's Chicago Fed segment had Austan Goolsbee calling February's 92,000 job losses a 'tough miss' while inflation sits stubbornly at 3% — which means the macro backdrop for small-cap growth names is still genuinely uncomfortable. CMED is still burning cash. But when you beat by 11 cents and cut reoperation rates by nearly three-quarters, the story starts writing itself — assuming anyone's still reading past the war headlines.